Le Lézard
Classified in: Health, Science and technology
Subjects: CCA, FVT

Pfenex to Report Fourth Quarter and Full Year 2017 Results and Provide Business Update on Thursday, March 15, 2018

SAN DIEGO, March 8, 2018 /PRNewswire/ -- Pfenex Inc. (NYSE American: PFNX) announced today that its fourth quarter and full year 2017 financial results will be released on Thursday, March 15, 2018, after the market close.  Pfenex management will host a corresponding conference call and a live webcast at 1:30pm PT/4:30pm ET on the same day to discuss the financial results and provide a business update.

Pfenex logo (PRNewsFoto/Pfenex)

Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) and reference Pfenex to access the call.  A replay of the conference call will be available approximately one hour after the call until March 22, 2018.  To access the teleconference replay please call 1-877-344-7529 (US) or 1-412-317-0088 (international) and enter the passcode 10117964.  The conference call will also be available as a webcast.  To access the webcast link please log on to www.pfenex.com (http://www.pfenex.com).

Pfenex investors and others should note that we announce material information to the public about the Company through a variety of means, including our website (http://www.pfenex.com), our investor relations website (http://pfenex.investorroom.com), press releases, SEC filings, public conference calls, corporate Twitter account (https://twitter.com/pfenex), Facebook page (https://www.facebook.com/Pfenex-Inc-105908276167776/timeline), and LinkedIn page (https://www.linkedin.com/company/pfenex-inc) in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD.  We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information.  Please note that this list may be updated from time to time.

About Pfenex Inc.

Pfenex is a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology® to improve protein therapies for unmet patient needs. Using the patented Pfenex Expression Technology platform, the Company has created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. The Company's lead product candidates are PF708, a therapeutic equivalent candidate to Forteo® (teriparatide) for the treatment of osteoporosis, and its novel anthrax vaccine candidates, Px563L and RPA563, funded through an advanced development contract with the U.S. government. In addition, the Company is developing hematology/oncology products in collaboration with Jazz Pharmaceuticals. Furthermore, our pipeline includes biosimilar candidates to Lucentis® and Neulasta®.


SOURCE Pfenex Inc.

These press releases may also interest you

at 03:00
BEVERLY HILLS, Calif., March 24, 2018 /PRNewswire-PRWeb/ -- ProstaGenix, named World's Best Prostate Supplement in 2017, proves effective not only by the National Health Federation and Prostatepillreport.com, but by the raving customer reviews...

23 mar 2018
Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 14, 2018 to file lead plaintiff applications in a securities class action lawsuit against Acadia...

23 mar 2018
WASHINGTON, March 23, 2018 /PRNewswire-PRWeb/ -- The Elizabeth Dole Foundation released the following statement today on the passage and signing of the omnibus spending bill: "Those of us who care deeply about military and veteran caregivers ? the...

23 mar 2018
Live Oak Village At Hammond Senior Living is now under new ownership and management and has been re-named Oak Park Village At Hammond Assisted Living and Memory Care after an extensive community renovation and upgrade to its offerings and amenities....

23 mar 2018
Arena Pharmaceuticals, Inc. today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the 17th Annual Needham Healthcare Conference on Tuesday, March 27 at 3:00 p.m. EDT.  The...

23 mar 2018
The Honourable Ginette Petitpas Taylor, Federal Minister of Health, will be announcing federal measures to increase access to opioid treatment. Government of Canada officials will also hold a media technical briefing (teleconference only) following...

News published on 8 march 2018 at 16:15 and distributed by: